Phase1/-2 study of Pomalidomide in myelofibrosis.
Mesa
Ruben A
RA
Pardanani
Animesh D
AD
Hussein
Kebede
K
Wu
Wenting
W
Schwager
Susan
S
Litzow
Mark R
MR
Hogan
William J
WJ
Tefferi
Ayalew
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D013792:Thalidomide; D011239:Prednisolone; C467566:pomalidomide